Breast Oncology Program

乳腺肿瘤学计划：摘要/摘要 HDFCCC乳腺肿瘤学（BR）计划的目标是降低乳腺癌发展的风险， 进展和死亡率，使用创新的方法和新的方法来揭示分子， 细胞和有针对性的网络，这些网络构成易感性、异质性和结果差异的基础。的 该计划的翻译性质意味着该计划中基于实验室的工作可以迅速转移到 临床试验BR计划的临床研究包括减少过度诊断，过度和不足， 通过风险评估，个体化筛查和预防， 措施，并通过改进肿瘤分类来定制治疗。BR研究集中在三个领域： (1)了解肿瘤异质性如何导致转移、休眠和治疗抗性; (2)利用试验设计和药物开发的创新开发新的治疗策略;（3）更好地 早期乳腺病变的特征，以提高筛查，预防和保健价值。

Breast Oncology Program: Summary/Abstract The goal of the HDFCCC Breast Oncology (BR) Program is to reduce the risk of breast cancer development, progression, and mortality using innovative approaches and novel methodologies to reveal the molecular, cellular, and targetable networks that underlie susceptibility, heterogeneity, and outcome disparities. The translational nature of the program means that laboratory-based work in the program can be rapidly moved into clinical trials. The clinical research of the BR Program includes reducing overdiagnosis, over- and under- treatment, and the burden of cancer therapy through risk assessment to individualize screening and prevention measures, and through improved tumor classification to tailor treatment. BR research focuses on three areas: (1) understanding how tumor heterogeneity contributes to metastasis, dormancy, and therapeutic resistance; (2) developing new therapeutic strategies using innovation in trial design and drug development; and (3) better characterizing early breast lesions to improve screening, prevention, and health care value.